A case series in partnership with My Gene Counsel to highlight the challenges genetics professionals and oncologists are grappling with as genetic testing is increasingly used in patient care.
The agency issued a new draft decision memo, outlining various criteria it intends to apply when determining coverage for current and future blood-based CRC screening tests.
The test analyzes substitutions, insertion and deletion alterations, and copy number alterations in 324 genes, along with some genomic signatures in solid tumors.
The company presented on the preliminary activity of RMC-4630 combined with Cotellic and said it is studying the SHP2 inhibitor alongside an AstraZeneca drug.
The company presented on the preliminary activity of RMC-4630 combined with Cotellic and said it is studying the SHP2 inhibitor alongside an AstraZeneca drug.
